This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), phar…

Advanced Solid TumorMetastatic Solid TumorEndometrial Cancer+4 more

~Estimated

~$10 – $8,750

MOMA TherapeuticsNCT06974110

Phase 1

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal o…

Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more

~Estimated

~$10 – $8,750

Medicenna Therapeutics, Inc.NCT05086692